KNE Stock Overview
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Kane Biotech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.10 |
52 Week High | CA$0.14 |
52 Week Low | CA$0.05 |
Beta | 0.56 |
1 Month Change | 5.00% |
3 Month Change | 40.00% |
1 Year Change | -12.50% |
3 Year Change | -38.24% |
5 Year Change | 50.00% |
Change since IPO | -94.00% |
Recent News & Updates
Shareholder Returns
KNE | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | -3.6% | 0.4% |
1Y | -12.5% | -27.7% | 9.3% |
Return vs Industry: KNE exceeded the Canadian Biotechs industry which returned -27.7% over the past year.
Return vs Market: KNE underperformed the Canadian Market which returned 9.3% over the past year.
Price Volatility
KNE volatility | |
---|---|
KNE Average Weekly Movement | 14.8% |
Biotechs Industry Average Movement | 12.9% |
Market Average Movement | 8.6% |
10% most volatile stocks in CA Market | 18.6% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: KNE's share price has been volatile over the past 3 months.
Volatility Over Time: KNE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Marc Edwards | https://kanebiotech.com |
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names.
Kane Biotech Inc. Fundamentals Summary
KNE fundamental statistics | |
---|---|
Market cap | CA$13.18m |
Earnings (TTM) | -CA$4.32m |
Revenue (TTM) | CA$2.74m |
5.0x
P/S Ratio-3.2x
P/E RatioIs KNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KNE income statement (TTM) | |
---|---|
Revenue | CA$2.74m |
Cost of Revenue | CA$1.43m |
Gross Profit | CA$1.31m |
Other Expenses | CA$5.63m |
Earnings | -CA$4.32m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.033 |
Gross Margin | 47.79% |
Net Profit Margin | -157.48% |
Debt/Equity Ratio | -116.8% |
How did KNE perform over the long term?
See historical performance and comparison